Literature DB >> 30105631

Lysine-specific demethylase 1 cooperates with BRAF-histone deacetylase complex 80 to enhance HIV-1 Tat-mediated transactivation.

Yu Liu1, Deyu Zhou1, Di Qi1, Jiabin Feng1, Zhou Liu1, Yue Hu1, Wenyuan Shen1, Chang Liu1, Xiaohong Kong2.   

Abstract

Despite the notable success of combination antiretroviral therapy, how to eradicate latent HIV-1 from reservoirs poses a challenge. The Tat protein plays an indispensable role in HIV reactivation and histone demethylase LSD1 promotes Tat-mediated long terminal repeats (LTR) activation. However, the role of LSD1 in remodeling chromatin and the role of its component BHC80 in activation of latent HIV-1 in T cells are unknown. Our findings indicate that LSD1 could decrease the level of histone H3 lysine 4 trimethylation (H3K4me3) at the HIV-1 promoter by recruiting histone lysine demethylase 5A (KDM5A) and preventing histone methyltransferase Set1A and WD-40 repeat protein 5 (WDR5) from binding to LTR. Moreover, BHC80 is necessary for LSD1-triggered LTR activation and assists LSD1 in activating LTR by binding to nucleotides 305-631 of LTR. In activated J-Lat-A2 cells, BHC80 expression was elevated and its isoform BHC80-6 promoted the association of BHC80 with LSD1. These results suggest that the LSD1-BHC80 complex enhances HIV-1 transcription by a decrease of H3K4me3 level at the viral promoter. Therefore, it might be used as a new drug target to reactivate latent HIV-1.

Entities:  

Keywords:  BRAF–histone deacetylase complex 80; HIV-1 Tat; Histone 3 lysine 4 trimethylation; Lysine-specific demethylase 1; Transactivation

Mesh:

Substances:

Year:  2018        PMID: 30105631     DOI: 10.1007/s11262-018-1589-5

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  49 in total

1.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

2.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

3.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

4.  UTX-1 regulates Tat-induced HIV-1 transactivation via changing the methylated status of histone H3.

Authors:  Hong-Sheng Zhang; Guang-Yuan Du; Yang Liu; Zhong-Guo Zhang; Zhen Zhou; Hu Li; Ke-Qing Dai; Xiao-Ying Yu; Xiao-Meng Gou
Journal:  Int J Biochem Cell Biol       Date:  2016-09-23       Impact factor: 5.085

5.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

6.  The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.

Authors:  Maria Giovanna Desimio; Erica Giuliani; Margherita Doria
Journal:  Virology       Date:  2017-07-06       Impact factor: 3.616

7.  Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.

Authors:  John R Horton; Amanda Engstrom; Elizabeth L Zoeller; Xu Liu; John R Shanks; Xing Zhang; Margaret A Johns; Paula M Vertino; Haian Fu; Xiaodong Cheng
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

8.  Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Authors:  Julian H Elliott; Fiona Wightman; Ajantha Solomon; Khader Ghneim; Jeffrey Ahlers; Mark J Cameron; Miranda Z Smith; Tim Spelman; James McMahon; Pushparaj Velayudham; Gregor Brown; Janine Roney; Jo Watson; Miles H Prince; Jennifer F Hoy; Nicolas Chomont; Rémi Fromentin; Francesco A Procopio; Joumana Zeidan; Sarah Palmer; Lina Odevall; Ricky W Johnstone; Ben P Martin; Elizabeth Sinclair; Steven G Deeks; Daria J Hazuda; Paul U Cameron; Rafick-Pierre Sékaly; Sharon R Lewin
Journal:  PLoS Pathog       Date:  2014-11-13       Impact factor: 6.823

9.  A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.

Authors:  Jun Wu; Ming-Tao Ao; Rui Shao; Hui-Ru Wang; Diao Yu; Mei-Juan Fang; Xiang Gao; Zhen Wu; Qiang Zhou; Yu-Hua Xue
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

10.  Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Authors:  Anthony Tumber; Andrea Nuzzi; Edward S Hookway; Stephanie B Hatch; Srikannathasan Velupillai; Catrine Johansson; Akane Kawamura; Pavel Savitsky; Clarence Yapp; Aleksandra Szykowska; Na Wu; Chas Bountra; Claire Strain-Damerell; Nicola A Burgess-Brown; Gian Filippo Ruda; Oleg Fedorov; Shonagh Munro; Katherine S England; Radoslaw P Nowak; Christopher J Schofield; Nicholas B La Thangue; Charlotte Pawlyn; Faith Davies; Gareth Morgan; Nick Athanasou; Susanne Müller; Udo Oppermann; Paul E Brennan
Journal:  Cell Chem Biol       Date:  2017-03-02       Impact factor: 8.116

View more
  1 in total

Review 1.  New targets for HIV drug discovery.

Authors:  Ana C Puhl; Alfredo Garzino Demo; Vadim A Makarov; Sean Ekins
Journal:  Drug Discov Today       Date:  2019-03-15       Impact factor: 7.851

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.